版本:
中国

BRIEF-Summit Therapeutics says completes enrolment of PhaseOut DMD

May 15 Summit Therapeutics Plc

* Summit completes enrolment of PhaseOut DMD, a phase 2 clinical trial of ezutromid in patients with dmd

* Summit Therapeutics - with dosing of last patient in trial, co has triggered $22 million milestone payment

* $22 million milestone payment is part of company's licence and collaboration agreement with Sarepta Therapeutics Inc Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐